Keros Therapeutics Valuation
| KROS Stock | USD 11.22 0.22 1.92% |
At this time, the firm appears to be undervalued. Keros Therapeutics secures a last-minute Real Value of $19.25 per share. The latest price of the firm is $11.22. Our model forecasts the value of Keros Therapeutics from analyzing the firm fundamentals such as Shares Outstanding of 40.56 M, operating margin of (17.51) %, and Return On Equity of -0.41 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Keros Therapeutics' valuation include:
Price Book 0.8105 | Enterprise Value | Enterprise Value Ebitda (13.05) | Price Sales 130.7125 | Enterprise Value Revenue 6.5 K |
Undervalued
Today
Please note that Keros Therapeutics' price fluctuation is not too volatile at this time. Calculation of the real value of Keros Therapeutics is based on 3 months time horizon. Increasing Keros Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Keros stock is determined by what a typical buyer is willing to pay for full or partial control of Keros Therapeutics. Since Keros Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Keros Stock. However, Keros Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 11.22 | Real 19.25 | Target 43.55 | Hype 11.64 | Naive 11.73 |
The intrinsic value of Keros Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Keros Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Keros Therapeutics helps investors to forecast how Keros stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Keros Therapeutics more accurately as focusing exclusively on Keros Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Keros Therapeutics' intrinsic value based on its ongoing forecasts of Keros Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Keros Therapeutics' closest peers.
Keros Therapeutics Cash |
|
Keros Valuation Trend
Keros Therapeutics' real value is important for investors to make better decisions and a more accurate overall view of Keros Therapeutics' financial worth over time. Using both Keros Therapeutics' enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
Keros Therapeutics Total Value Analysis
Keros Therapeutics is now estimated to have valuation of (77.85 M) with market capitalization of 464.03 M, debt of 18.86 M, and cash on hands of 215.62 M. The negative valuation of Keros Therapeutics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Keros Therapeutics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(77.85 M) | 464.03 M | 18.86 M | 215.62 M |
Keros Therapeutics Investor Information
About 98.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.81. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Keros Therapeutics recorded a loss per share of 5.0. The entity had not issued any dividends in recent years. Based on the key indicators related to Keros Therapeutics' liquidity, profitability, solvency, and operating efficiency, Keros Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April.Keros Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Keros Therapeutics has an asset utilization ratio of 0.58 percent. This implies that the Company is making $0.005764 for each dollar of assets. An increasing asset utilization means that Keros Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Keros Therapeutics Ownership Allocation
The majority of Keros Therapeutics outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Keros Therapeutics to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Keros Therapeutics. Please pay attention to any change in the institutional holdings of Keros Therapeutics as this could imply that something significant has changed or is about to change at the company.Keros Therapeutics Profitability Analysis
The company reported the previous year's revenue of 3.55 M. Net Loss for the year was (187.35 M) with loss before overhead, payroll, taxes, and interest of (14.74 M).About Keros Therapeutics Valuation
The stock valuation mechanism determines Keros Therapeutics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Keros Therapeutics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Keros Therapeutics. We calculate exposure to Keros Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Keros Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 3.5 M | 1.9 M | |
| Pretax Profit Margin | (52.69) | (55.33) | |
| Operating Profit Margin | (59.39) | (62.36) | |
| Net Loss | (52.78) | (55.41) | |
| Gross Profit Margin | (5.06) | (4.80) |
Keros Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Keros Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 37.4 M |
Keros Therapeutics Current Valuation Indicators
Keros Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Keros Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Keros Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Keros Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Keros Therapeutics' worth.Additional Tools for Keros Stock Analysis
When running Keros Therapeutics' price analysis, check to measure Keros Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Keros Therapeutics is operating at the current time. Most of Keros Therapeutics' value examination focuses on studying past and present price action to predict the probability of Keros Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Keros Therapeutics' price. Additionally, you may evaluate how the addition of Keros Therapeutics to your portfolios can decrease your overall portfolio volatility.